{"name":"Ocugen","slug":"ocugen","ticker":"OCGN","exchange":"NASDAQ","domain":"ocugen.com","description":"Ocugen, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies, biologic, and vaccines that improve patients' health. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease. It is involved in the development of OCU200, a novel recombinant fusion protein for the treatment of diabetic macular edema, diabetic retinopathy, and wet age-related macular degeneration; and NeoCart, an autologous chondrocyte-derived neocartilage for the repair of knee cartilage injuries","hq":"Malvern, PA","founded":0,"employees":"116","ceo":"Shankar Musunuri","sector":"Ophthalmology / Gene Therapy","stockPrice":1.45,"stockChange":-0.02,"stockChangePercent":-1.36,"marketCap":"$491M","metrics":{"revenue":4413000,"revenueGrowth":0,"grossMargin":0,"rdSpend":39750000,"netIncome":-67846000,"cash":39462000,"dividendYield":0,"peRatio":-6.4,"fiscalYear":"FY2021"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2034-06-01","label":"OCU400 patent cliff ($0.0B at risk)","drug":"OCU400","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[{"name":"Infectious Disease","slug":"infectious-disease","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Corticosteroid Eye Drop","genericName":"Corticosteroid Eye Drop","slug":"corticosteroid-eye-drop","indication":"Treatment of non-infectious uveitis affecting the posterior segment of the eye","status":"phase_2"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"OCU400 High Dose","genericName":"OCU400 High Dose","slug":"ocu400-high-dose","indication":"Other","status":"phase_1"}]}],"pipeline":[{"name":"Corticosteroid Eye Drop","genericName":"Corticosteroid Eye Drop","slug":"corticosteroid-eye-drop","phase":"phase_2","mechanism":"Corticosteroid eye drops reduce inflammation in the eye by suppressing the immune system.","indications":["Treatment of non-infectious uveitis affecting the posterior segment of the eye"],"catalyst":""},{"name":"OCU400 High Dose","genericName":"OCU400 High Dose","slug":"ocu400-high-dose","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[{"date":"2024-02-28","type":"earnings","headline":"Ocugen Reports Fourth Quarter and Full Year 2023 Financial Results","summary":"Ocugen reported its financial results for the fourth quarter and full year 2023, with a net loss of $44.4 million and $183.6 million, respectively.","drugName":"","sentiment":"neutral"},{"date":"2023-12-18","type":"deal","headline":"Ocugen Announces Collaboration with Bharat Biotech to Develop COVID-19 Vaccine","summary":"Ocugen announced a collaboration with Bharat Biotech to develop a COVID-19 vaccine, with Bharat Biotech providing the vaccine candidate and Ocugen responsible for clinical development and commercialization in the US.","drugName":"","sentiment":"positive"},{"date":"2023-09-11","type":"regulatory","headline":"FDA Grants Fast Track Designation to Ocugen's OCU400 for the Treatment of Retinitis Pigmentosa","summary":"The FDA granted fast track designation to Ocugen's OCU400 for the treatment of retinitis pigmentosa, a rare genetic disorder that affects the retina.","drugName":"","sentiment":"positive"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMivwFBVV95cUxPcWNKUHEtYzdBSEdKQl8wXzYyNkVtUzhLMDhwTjBxUG5jbERqaDlWaW9iUENHWXNwS240OWljY1luU3V0VXlJU1l4ZmhkWTNVM0JFNUdaNXJWZWF6MDlnV1BONHNyUng0aDY3N09aZE5NeDBvR3JSbF8xZTJ2RlNDODF1emdORGx3ZXJvMUZFNmJIMWFiMHFYeGV2RXN4MlZ2UW45LTVIZEJ3N19UQ0pUOEVDRlRVdDVIM3JadVF4QQ?oc=5","date":"2026-04-02","type":"trial","source":"TradingView","summary":"OCGN Completes Early Enrollment in Pivotal Stargardt Disease Study - TradingView","headline":"OCGN Completes Early Enrollment in Pivotal Stargardt Disease Study","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiXkFVX3lxTE9vdU9mVTRPeHBFRC0xNGFXMVpiTUFweTB2Vms5V0JrQ3puS2FtbUJlekNtSXZ2YmpHdUFEWVpra3EtT1ZsYmZOT2JJejExZWYyLTRPaHJlQ3pVd2p6N1HSAWNBVV95cUxQSHp6ZDhBS2FnaWNWT2RJdk50QVMwVVN2TGF0d0xUUDJoZVVHN0FWR3FILVlKSUxYUVdLZUpnenB3MkJLd1k5VUJsRnBUYnJDUVVyV05PNEZSSnZKeWE5SXdta0E?oc=5","date":"2026-04-02","type":"trial","source":"Bitget","summary":"OCGN Finishes Initial Participant Registration for Key Stargardt Disease Trial - Bitget","headline":"OCGN Finishes Initial Participant Registration for Key Stargardt Disease Trial","sentiment":"neutral"},{"date":"2026-03-27","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi5gFBVV95cUxQc3BDallaV3RQMGVoSGEzV25fYWxrM3lmeE1GcmoxR3IySnFPeV9fS3gyU2pzX05jT1lnUWdfQ25yeVVycTh5UDNXT2w5UVN5N1Z5LTJTYTE5MEk5OV9jTk8td1JOX1ZGcGxIcy1aeXBaNHIwTm1nTmktbTd5am5zX1JNZmpOR0xiY2tidjBYLVJXOXpvNXYyMWNMMGl0OS1KZUxCMGs5N0g3UGdYSVc5b1FpT2U4MEVuT2tua25TS0NNaGhveFJvd3VTZ0hlZVVXcFJaMC00LXhDejJkekFCYUM1ZmpHZw?oc=5","date":"2026-03-25","type":"trial","source":"The Globe and Mail","summary":"Ocugen Falls as Gene Therapy for Eye Disease Lags in Phase II Study - The Globe and Mail","headline":"Ocugen Falls as Gene Therapy for Eye Disease Lags in Phase II Study","sentiment":"neutral"},{"date":"2026-03-24","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"date":"2026-03-20","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"date":"2026-03-04","type":"earnings","source":"SEC EDGAR","summary":"10-K filed with SEC: 10-K","headline":"Annual Report (10-K) Filed","sentiment":"neutral"},{"date":"2026-03-04","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"date":"2026-03-04","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"date":"2026-02-09","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"date":"2026-01-23","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"date":"2026-01-21","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipwFBVV95cUxPNEM2OVRXZktweEFVX1czOGFfV3doMlp0QnRXZ2FiNlpQUW55dDRXVW1LZ1FTVEdXZFkzcWtfcVZlQUJ2YmpyX3o1Z3FVcUptSkxuT0V4bVlFNzMwOEZIWEJEWTBkSGlwclB0WWJUTTF0em9rMDF3VHd0WUtCTWpRWjh0NUNFYXhTZTY5M2FYU2tnZzE5bUxwa3ZnVG8zajdCSGRabjdGWQ?oc=5","date":"2026-01-16","type":"trial","source":"Seeking Alpha","summary":"Ocugen: Why I Don't Read Too Much Into The Selloff On Phase 2 GA Data (NASDAQ:OCGN) - Seeking Alpha","headline":"Ocugen: Why I Don't Read Too Much Into The Selloff On Phase 2 GA Data (NASDAQ:OCGN)","sentiment":"neutral"},{"date":"2026-01-15","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"date":"2025-12-18","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"}],"patents":[{"drugName":"OCU400","drugSlug":"generic","patentNumber":"","type":"Patent Cliff","expiryDate":"2034-06-01","territory":"US","annualRevenue":0}],"drugCount":2,"phaseCounts":{"phase_2":1,"phase_1":1},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Regeneron Pharmaceuticals","Alcon","Bausch Health"],"therapeuticFocus":["Ophthalmology","Gene Therapy"],"financials":{"source":"sec_edgar+yahoo","revenue":0,"revenuePeriod":"2021-12-31","revenueHistory":[{"value":0,"period":"2021-12-31"},{"value":42620,"period":"2020-12-31"},{"value":0,"period":"2019-12-31"}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":39750000,"rdSpendHistory":[{"period":"2025-12-31","value":39750000},{"period":"2024-12-31","value":32126000},{"period":"2023-12-31","value":39573000},{"period":"2022-12-31","value":56159000}],"sgaSpend":27579000,"operatingIncome":-62916000,"operatingIncomeHistory":[{"period":"2025-12-31","value":-62916000},{"period":"2024-12-31","value":-54757000},{"period":"2023-12-31","value":-65531000},{"period":"2022-12-31","value":-89071000}],"netIncome":-67846000,"netIncomeHistory":[{"period":"2025-12-31","value":-67846000},{"period":"2024-12-31","value":-54054000},{"period":"2023-12-31","value":-63078000},{"period":"2022-12-31","value":-86804000}],"eps":-0.2,"epsHistory":[{"period":"2024-12-31","value":-0.2},{"period":"2023-12-31","value":-0.26},{"period":"2022-12-31","value":-0.38},{"period":"2021-12-31","value":-0.3}],"cash":39462000,"cashHistory":[{"period":"2025-12-31","value":18571000},{"period":"2024-12-31","value":58514000},{"period":"2023-12-31","value":39462000},{"period":"2022-12-31","value":77563000}],"totalAssets":43516000,"totalLiabilities":55682000,"totalDebt":33144000,"equity":-12166000,"operatingCashflow":-56964000,"operatingCashflowHistory":[{"period":"2025-12-31","value":-56964000},{"period":"2024-12-31","value":-42142000},{"period":"2023-12-31","value":-62054000},{"period":"2022-12-31","value":-60079000}],"capex":-185000,"capexHistory":[{"period":"2025-12-31","value":-185000},{"period":"2024-12-31","value":-3385000},{"period":"2023-12-31","value":-10476000},{"period":"2022-12-31","value":-4457000}],"freeCashflow":-57149000,"dividendsPaid":null,"buybacks":0,"employees":116,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[{"sga":8117000,"ebit":-17857000,"ebitda":-17267000,"period":"2026-03-31","revenue":1533000,"epsBasic":-0.06,"netIncome":-19177000,"rdExpense":11255000,"epsDiluted":-0.06,"grossProfit":null,"operatingIncome":-17839000},{"sga":6133000,"ebit":-16374000,"ebitda":-16374000,"period":"2025-12-31","revenue":-193000,"epsBasic":-0.06,"netIncome":-17706000,"rdExpense":10669000,"epsDiluted":-0.06,"grossProfit":null,"operatingIncome":-16995000},{"sga":8228000,"ebit":-18737000,"ebitda":-17787000,"period":"2025-09-30","revenue":1752000,"epsBasic":-0.0642,"netIncome":-20051000,"rdExpense":11149000,"epsDiluted":-0.0642,"grossProfit":null,"operatingIncome":-17625000},{"sga":6766000,"ebit":-13795000,"ebitda":-12554000,"period":"2025-06-30","revenue":1373000,"epsBasic":-0.05,"netIncome":-14739000,"rdExpense":8402000,"epsDiluted":-0.05,"grossProfit":null,"operatingIncome":-13795000},{"sga":6453000,"ebit":-14093000,"ebitda":-13498000,"period":"2025-03-31","revenue":1481000,"epsBasic":-0.05,"netIncome":-15350000,"rdExpense":9529000,"epsDiluted":-0.05,"grossProfit":null,"operatingIncome":-14501000}]},"ciks":null,"lastFiledAt":null},"yahoo":{"currentPrice":1.45,"previousClose":1.47,"fiftyTwoWeekHigh":2.73,"fiftyTwoWeekLow":0.64,"fiftyTwoWeekRange":"0.64 - 2.725","fiftyDayAverage":1.84,"twoHundredDayAverage":1.49,"beta":2.31,"enterpriseValue":503139968,"forwardPE":-6.4,"priceToBook":-37.18,"priceToSales":111.23,"enterpriseToRevenue":114.01,"enterpriseToEbitda":-8.22,"pegRatio":0,"ebitda":-61191000,"ebitdaMargin":0,"freeCashflow":-33116000,"operatingCashflow":-56964000,"totalDebt":33144000,"debtToEquity":0,"currentRatio":1.06,"returnOnAssets":-63.1,"returnOnEquity":-776.9,"analystRating":"1.1 - Strong Buy","recommendationKey":"strong_buy","numberOfAnalysts":7,"targetMeanPrice":11.57,"targetHighPrice":22,"targetLowPrice":7,"dividendRate":0,"payoutRatio":0,"fiveYearAvgDividendYield":0,"exDividendDate":0,"insiderHeldPercent":1.7,"institutionHeldPercent":21.8,"sharesOutstanding":338521856,"floatShares":306918427,"sharesShort":67890507,"shortRatio":7.36,"shortPercentOfFloat":20.7,"epsTrailing":-0.24,"epsForward":-0.23,"revenuePerShare":0.01,"bookValue":-0.04,"officers":[{"age":61,"name":"Dr. Shankar  Musunuri M.B.A., Ph.D.","title":"Co-Founder, CEO & Chairman"},{"age":43,"name":"Dr. Arun  Upadhyay Ph.D.","title":"Chief Scientific Officer and Head of Research & Development"},{"age":41,"name":"Dr. Huma  Qamar CMI, M.D., M.P.H.","title":"Chief Medical Officer"},{"age":48,"name":"Ms. Rita  Johnson-Greene M.B.A.","title":"Chief Financial Officer"},{"age":null,"name":"Mr. Paul  Staid","title":"Executive Vice President of Operations"},{"age":null,"name":"John  Kouch J.D.","title":"General Counsel"},{"age":null,"name":"Ms. Tiffany J. Hamilton M.B.A.","title":"AVP & Head of Corporate Communications"},{"age":null,"name":"Ms. Kristen  Craft","title":"Head of People & Culture"}],"industry":"Biotechnology","irWebsite":"","website":"https://www.ocugen.com","phone":"484-328-4701"}}